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   ABSTRACT   
  Objective      Identify serum biomarkers modulated by 
golimumab treatment and associated with clinical 
response in patients with ankylosing spondylitis (AS).   
  Methods      Sera were collected at weeks 0, 4 and 14 
from 100 patients with active AS in the GO–RAISE 
study. Patients were randomly assigned subcutaneous 
injections of placebo, golimumab 50 mg, or golimumab 
100 mg every 4 weeks.  Samples were tested for select 
inﬂ  ammatory, bone and cartilage markers, and protein 
proﬁ  ling was also performed.   
  Results      Golimumab treatment resulted in signiﬁ  cant 
decreases in several serum proteins at weeks 4 and 
14 compared with placebo. Patients who achieved 
clinical response at week 14, as assessed by a ≥20% 
improvement in the Assessment in SpondyloArthitis 
international Society response criteria (ASAS 20), 
demonstrated a distinct biomarker proﬁ  le with lower 
levels of acute phase reactants and inﬂ  ammatory 
biomarkers compared with patients who did not. Notably, 
combinations of two or three biomarkers assessed at 
baseline were predictive of various clinical outcomes 
(ASAS 20, Bath ankylosing spondylitis disease activity 
index 50 or Bath ankylosing spondylitis functional index) 
using a logistic regression analysis, and the overall 
predictive values for these combined biomarkers were 
greater than observed for C-reactive protein (CRP) alone.   
  Conclusion      Golimumab modulated acute phase 
reactants and inﬂ  ammatory markers in patients with 
active AS. Speciﬁ  c combinations of biomarkers at 
baseline demonstrated a stronger prediction for clinical 
efﬁ  cacy than CRP alone. These data provide insights into 
the mechanism of golimumab on inﬂ  ammatory processes 
driving AS pathology, and may have utility in managing 
the  treatment  of  patients  with  AS.       
  While the pathogenesis of ankylosing spondyli-
tis (AS) remains unknown, patients with AS have 
been shown to have markers indicative of increased 
numbers of T cells and macrophage activation. 
In addition, the expression of a variety of proin-
ﬂ  ammatory cytokines, as well as markers of bone 
metabolism, are increased in the sacroiliac joints 
and entheses of patients with AS. Elevated serum 
levels of inﬂ  ammatory markers (including tumour 
necrosis factor (TNF)α, interleukin (IL-) 6,  1   vascu-
lar endothelial growth factor (VEGF),  2   Intercellular 
adhesion molecule-1 (ICAM-1))  3     and markers of 
bone metabolism (bone alkaline phosphatase (BAP) 
and osteocalcin) have previously been shown to be 
associated with active AS.  4   
  Elevated TNFα levels in the serum have been 
shown to correlate with elevated IL-6 and C-reactive 
protein (CRP) levels in patients with AS.  1   In addi-
tion, serum matrix metalloproteinase -3 (MMP-3) 
levels have been shown to correlate with disease 
activity as assessed by the Bath ankylosing spon-
dylitis disease activity index (BASDAI) score  5   and 
to be an independent predictor of structural dam-
age  6   in patients with AS. Patients with spondyloar-
thropathies also have elevated levels of ICAM-1, 
which has been shown to correlate with IL-6 and 
CRP levels.  3   IL-6 has been shown to be elevated 
in the serum of AS patients and to decrease fol-
lowing treatment with inﬂ  iximab.  7   Furthermore, 
a recent study has shown that the combination of 
CRP and serum amyloid A were weakly predic-
tive of clinical response to anti-TNFα therapy, and 
changes in these markers over 3 months signiﬁ  -
cantly correlated with changes in disease activity 
as assessed by the BASDAI score.  8   Elevated serum 
levels of VEGF were found to correlate signiﬁ  cantly 
with measures of disease activity such as BASDAI 
score and CRP in patients with AS.  2   TNFα inhibi-
tion has been shown to reduce levels of VEGF in 
patients with AS,  7   and changes in VEGF levels have 
also been shown to correlate with changes in CRP, 
erythrocyte sedimentation rate, and BASDAI score 
in AS patients receiving anti-TNFα therapy.  9   
  AS is characterised by joint inﬂ  ammation, 
destruction and repair. Assessment of markers 
associated with bone turnover in AS has contrib-
uted to elucidating key pathways linked to the 
disease. During destruction of joint tissues, the 
cross-links pyridinoline and deoxypyridinoline 
that bridge between adjacent molecules of types I, 
II and III collagen in bone, synovium and cartilage 
are released into the circulation as small peptides.  10   
In addition, the rate of type I collagen synthesis in 
bone can be evaluated by measuring serum levels of 
N-terminal propeptide of type 1 collagen (P1NP).  10   
In addition, levels of the bone formation markers 
BAP and osteocalcin have been shown to increase 
within 4 weeks in patients with AS who received 
anti-TNFα therapy, and these changes correlated 
with increases in the bone mineral density of the 
spine and hip.  11   Increases in BAP levels have also 
been demonstrated at 36 and 52 weeks following 
anti-TNFα therapy.  9   
  ▶  Additional supplementary 
ﬁ  gure 1 is published online 
only. To view the ﬁ  les 
please visit the journal 
online (http://ard.bmj.com/
content/71/5.toc). 
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  In the current study, we evaluated approximately 100 different 
serum proteins using multiplex and singleplex assay platforms 
(ELISA and Luminex) to identify markers modulated by treat-
ment with golimumab (a human monoclonal antibody to TNFα) 
in patients with active AS. Comparisons of baseline markers, 
as well as the change from baseline to week 4, were evalu-
ated against several clinical response measures (Assessment in 
Spondyloarthitis International Society response criteria (ASAS), 
BASDAI and the Bath ankylosing spondylitis functional index 
(BASFI)). As these analyses yielded multiple markers at baseline 
that were strongly associated with these clinical response mea-
sures, some additional comparisons to evaluate the potential 
to predict clinical response in patients treated with golimumab 
were conducted using just the baseline biomarkers. 
  METHODS 
  Details of the GO–RAISE study have been published previ-
ously.  12   Brieﬂ   y, patients with AS for 3 months or more, a 
BASDAI score of 4 or greater, a spinal pain assessment score 
of 4 or greater, and an inadequate response to current or previ-
ous non-steroidal anti-inﬂ  ammatory drugs or disease-modifying 
antirheumatic drugs were eligible for the study. Approximately 
20% of patients across all treatment groups were receiving 
methotrexate at baseline. 
  Patients were randomly assigned in a 1:1.8:1.8 ratio to receive 
subcutaneous injections of placebo (n=78), golimumab 50 mg 
(n=138) or golimumab 100 mg (n=140) every 4 weeks. At week 
16, patients who had less than a 20% improvement from base-
line in both total back pain and morning stiffness entered an 
early escape arm in which patients in the placebo group received 
golimumab 50 mg and patients in the golimumab 50-mg group 
had their dose increased to 100 mg. Patients who were originally 
assigned to the golimumab 100-mg group were not eligible for 
early escape. 
  In the GO–RAISE biomarker substudy, the following clini-
cal endpoints were compared against biomarker data. Clinical 
response was deﬁ  ned as at least a 20% improvement in the 
(ASAS 20),  13   and physical function was evaluated using the 
BASFI.  14   Also, disease activity was evaluated using the BASDAI 
score,  15   with patients achieving a 50% or greater improvement 
in the BASDAI score deﬁ  ned as BASDAI 50 responders. 
  Samples were collected for this prospectively planned study 
at 15 biomarker substudy sites (US and non-US). Serum   samples 
were evaluated for the ﬁ  rst 100 patients enrolled in the substudy 
who had samples collected at weeks 0, 4 and 14. Samples were 
tested for selected markers using Luminex and ELISA platforms 
by Quintiles Laboratories (Marietta, Georgia, USA) and Paciﬁ  c 
Biometrics (Seattle, Washington, USA). The individual mark-
ers selected for these analyses included BAP, COL 2–3/4C long 
neoepitope, deoxypyridinoline, hyaluronic acid, IL-6, IL-8, 
ICAM-1, MMP-3, P1NP, osteocalcin, pyridinoline, TNFα and 
VEGF. The serum samples were also analysed by Rules Based 
Medicine (Austin, Texas, USA) using the HumanMAP version 
1.6 protein proﬁ  ling analysis.  16   The HumanMAP proﬁ  ling analy-
sis comprised 88 analytes, along with an additional four analytes 
included as part of the analytical panel (IL-17, IL-18, IL-23 and 
glutathione-S-transferase). Several of the selected markers listed 
above (ie, IL-6, IL-8, ICAM-1, MMP-3, TNFα and VEGF) were 
analysed as individual markers as well as being included in the 
protein proﬁ  ling analysis. In an independent study conducted 
by the sponsor, clinical samples were analysed repeatedly using 
the HumanMAP proﬁ   le and were found to have acceptable 
reproducibility. 
  Only markers for which at least 20% of all samples were above 
the lower limit of quantiﬁ  cation were included in these reported 
results. Biomarker data were log  2  -transformed, and changes 
from baseline were evaluated using one-sample t tests. OR and 
corresponding p values were generated to assess the association 
between biomarker levels (baseline and change from baseline 
to week 4) and clinical response. In addition, logistic regression 
modelling was employed to determine the ability of various 
biomarkers at baseline to predict clinical response at week 14. 
Prediction models were developed using logistic regression that 
included no adjustment for age, sex or concomitant medications 
at baseline. Model accuracy (sensitivity, speciﬁ  city, negative pre-
dictive value (NPV), positive predictive value (PPV)) was esti-
mated using cross-validation. To account for multiple statistical 
testing, a false discovery rate (FDR) analysis was performed. The 
FDR analysis was used to deﬁ  ne a p value threshold at which 
the FDR would be approximately 5–10%, and accounted for the 
fact that the biomarkers were not independent factors, but also 
had marker-to-marker interactions.   
  RESULTS 
  Of the 92 biomarkers that were evaluated in protein proﬁ  ling, 
63 (68%) met the prespeciﬁ  ed criteria for inclusion in the data 
analysis (ie, at least 20% of all samples were above the lower 
limit of quantiﬁ  cation for that analyte). As discussed in further 
detail below, signiﬁ  cant relationships between biomarker lev-
els and clinical response were observed in the following general 
  biomarker categories: acute phase reactants (α-1 antitrypsin, 
CRP, haptoglobin, serum amyloid P, von Willebrand factor); 
bone metabolism factors (P1NP, osteocalcin, deoxypyridino-
line); coagulation factors (plasminogen activator inhibitor 1); 
  haematological factors (complement 3, ferritin); inﬂ  ammatory 
markers (chemokine (C-C motif) ligand 5 (RANTES) (CCL5), 
epithelial-derived neutrophil-activating protein 78 (ENA-78), 
 Table  1     Baseline characteristics of the overall study population and 
the biomarker substudy population   
  Placebo
Golimumab 
50 mg
Golimumab 
100 mg
Overall study population
 N 78 138 140
  Age (years) 40.6 ± 12.7   39.2 ± 12.5   38.6 ± 11.3
  Sex (% men) 71   74   70
  Race (% Caucasian) 73   75   73
  Years of inﬂ  ammatory back pain 16.1 ± 11.5   13.6 ± 10.4   13.2 ± 10.4
  Serum CRP (µg/ml)   1.9 ± 2.3     1.8 ± 1.8     1.8 ± 2.1
  HLA-B27 positive (%) 85   82   84
  Back pain (10-cm VAS)   7.5 ± 1.6     7.1 ± 1.5     7.6 ± 1.6
  BASDAI score (0–10)   6.6 ± 1.5     6.5 ± 1.6     6.9 ± 1.5
  BASFI score (0–10)   5.1 ± 2.3     5.0 ± 2.4     5.2 ± 2.6
Biomarker substudy population
  N 24  37  39
  Age (years) 42.3 ± 11.2   39.2 ± 12.7   40.4 ± 11.8
  Sex (% men) 67   76   64
  Race (% Caucasian) 88   95   95
  Years of inﬂ  ammatory back pain 18.1 ± 10.3   13.7 ± 10.0   16.7 ± 12.5
  Serum CRP (µg/ml)   1.2 ± 1.2     1.9 ± 1.7     1.8 ± 2.0
  HLA-B27 positive (%) 83   73   82
  Back pain (10-cm VAS)   7.7 ± 1.4     7.6 ± 1.3     7.6 ± 1.4
  BASDAI score (0–10)   6.7 ± 1.6     7.2 ± 1.3     7.1 ± 1.3
  BASFI score (0–10)   5.9 ± 2.0   6.3  ±  2.2   5.8  ±  2.2
      Data shown are mean ± SD or percentage of patients.   
    BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing 
spondylitis functional index; CRP, C-reactive protein; HLA, human leucocyte antigen; 
VAS, visual analogue scale.     
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IL-6, ICAM-1, macrophage inﬂ  ammatory protein 1β, MMP-3, 
tissue inhibitor of metalloproteinases 1 (TIMP-1), TNF recep-
tor II, VEGF); metabolic factors (apolipoprotein C3, leptin); 
and other markers (insulin, sex hormone-binding globulin, 
thyroxine-binding globulin). A comparison of the baseline 
characteristics for patients in the biomarker substudy indicated 
that the treatment groups were generally well balanced with 
the exception of mean serum CRP level-, which was numeri-
cally, but not statistically (data not shown), lower in the pla-
cebo group (1.2 μg/ml) compared with the golimumab 50-mg 
(1.9 μg/ml) and 100-mg (1.8 μg/ml) groups of the substudy. 
In addition, the baseline characteristics of the biomarker sub-
study patients (n=100) were generally consistent with those 
of the overall GO–RAISE study population (n=356), although 
there was a higher proportion of Caucasians in the substudy 
than in the overall population (  table 1  ).  
    Changes from baseline in biomarker levels 
  As an initial evaluation, post-treatment changes in biomarkers 
were compared between the placebo and golimumab treatment 
groups. Signiﬁ  cantly greater changes from baseline to week 4 in 
the mean levels of 16 markers were observed in the golimumab 
groups compared with the placebo group. Log  2  -transformed 
values for these markers at baseline and week 4 are shown 
in   ﬁ  gure 1A  . Markers with signiﬁ  cant changes included acute 
phase reactants (CRP, haptoglobin, serum amyloid P), comple-
ment-related markers (complement 3), haematological factors 
(ferritin), inﬂ  ammatory markers (CCL5, ENA-78, ICAM-1, mac-
rophage inﬂ  ammatory protein 1β, MMP-3, TIMP-1, TNF recep-
tor II), metabolic markers (plasminogen activator   inhibitor-1), 
and other markers (thyroxine-binding globulin, sex hormone-
  binding globulin, VEGF); see supplementary ﬁ   gure 1, avail-
able online only).         
Figure 1  Heatmaps representing biomarker levels at baseline, week 4 or week 14 in the placebo and golimumab groups (A) and for Assessment in 
Spondyloarthitis International Society response criteria (ASAS 20) responders and non-responders (B). Data were log2-transformed and then scaled to 
a mean of 0. Negative values (red) are thus below the mean and positive values (white) are above the mean (see ﬁ  gure key).
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    Differences in biomarker levels between ASAS 20 responders 
and non-responders 
  Distinct biomarker proﬁ   les were observed for golimumab-
treated patients who achieved an ASAS 20 response at week 14 
versus those who did not (  ﬁ  gure 1B  ). ASAS 20 responders had 
lower baseline levels of insulin, von Willebrand factor and the 
metabolic factors apolipoprotein C3 and leptin than did ASAS 
20 non-responders. ASAS 20 responders also had lower levels 
of these biomarkers at weeks 4 or 14, as well as lower levels 
of complement 3, the acute phase reactants CRP and serum 
amyloid P and the inﬂ  ammatory marker IL-6 compared with 
ASAS 20 non-responders. In contrast, ASAS 20 responders had 
elevated levels of the acute phase reactant haptoglobin and the 
inﬂ  ammatory marker ENA-78 compared with ASAS 20 non-
responders at weeks 4 and 14. Finally, at baseline, week 4 and 
week 14, ASAS 20 responders had signiﬁ  cantly lower levels of 
the bone metabolism factors P1NP and osteocalcin compared 
with ASAS 20 non-responders.   
    Associations between biomarker levels and clinical 
endpoints in golimumab-treated patients 
  Associations between baseline serum biomarker levels and the 
achievement of clinical response were assessed via robust logistic 
regression analyses. The resulting OR, shown in   table 2   for the 
association between baseline biomarker levels and the achieve-
ment of ASAS 20 (yes/no) at week 14 as well as the degree of 
change in BASDAI or BASFI score from baseline to week 14, 
indicate signiﬁ  cant relationships between baseline biomarkers 
and measures of clinical improvement. Many of these markers 
are associated with all three measures of clinical improvement.   
  Baseline levels of insulin, the metabolic factors apolipoprotein 
C3 and leptin, the acute phase reactant haptoglobin, the inﬂ  am-
matory marker IL-6 and the bone metabolism factors osteocal-
cin, P1NP and deoxypyridinoline were associated with ASAS 20 
response at week 14. These same markers, with the exception of 
IL-6 and the addition of ENA-78, were also associated with the 
change in BASFI score from baseline to week 14. Baseline levels 
of the bone metabolism factor deoxypyridinoline were associated 
with ASAS 20 response at week 14 and the change in BASDAI 
score from baseline to week 14. Baseline levels of ENA-78, P1NP, 
osteocalcin and IL-6 were also associated with changes from 
baseline to week 14 in the BASDAI score (  table 2  ). 
  Changes from baseline to week 4 in levels of complement 3, the 
acute phase reactants α-1 antitrypsin, CRP and haptoglobin and 
the inﬂ  ammatory marker IL-6 were associated with the achieve-
ment of ASAS 20 response at week 14 and also with changes from 
baseline to week 14 in both BASDAI and BASFI scores (  table 2  ). In 
addition, changes from baseline to week 4 in thyroxine-binding 
globulin and serum amyloid P levels were associated with changes 
from baseline to week 14 in both BASFI and BASDAI scores.   
    Utility of CRP versus biomarker combinations at baseline to 
predict clinical improvement at week 14 
  Using a logistic regression analysis, the best combinations of 
markers (baseline levels) that were associated with the achieve-
ment of ASAS 20 and BASDAI 50 responses at week 14 and 
a 2 unit or greater improvement from baseline to week 14 in 
the BASFI score were determined (  table 3  ). Results of similar 
comparisons employing the change from baseline to week 4 
in biomarker levels yielded weaker prediction power (data not 
shown) than ﬁ  ndings based on baseline biomarker data.   
  Baseline levels of P1NP (OR 7.24, p=0.001) and insulin (OR 
0.61, p=0.007) were the strongest predictors of ASAS 20 response 
at week 14, with an NPV of 77% and a PPV of 85%. In compari-
son, the NPV and PPV of a model using CRP as the sole predictor 
of ASAS 20 response (OR 1.36, p=0.070) were 56% and 78%, 
respectively. 
  The strongest predictors of BASDAI 50 response at week 14 
were baseline levels of leptin (OR 0.50, p=0.0004), immuno-
globulin M (OR 3.46, p=0.006) and VEGF (OR 2.20, p=0.026). 
 Table  2     OR from robust logistic regression analysis testing the association between biomarker levels 
(baseline and changes from baseline to week 4) and clinical endpoints (ASAS 20 response at week 14, 
changes from baseline to week 14 in BASFI score and changes from baseline to week 14 in BASDAI score)   
  ASAS 20 at week 14
BASFI change from 
baseline to week 14
BASDAI change from 
baseline to week 14
Biomarker OR p Value OR p Value OR p Value
Baseline
 Apolipoprotein  C3 0.35 0.019 0.41 0.036 0.69 NS
 Deoxypyridinoline 6.49 0.033 4.15 NS 7.48 0.017
  Epithelial neutrophil activating peptide-78 2.00 NS 2.44 0.031 3.12 0.010
 Haptoglobin 1.70 0.046 1.72 0.040 1.70 NS
 Insulin 0.63 0.009 0.66 0.013 0.77 NS
 Interleukin  6 1.80 0.017 1.47 NS 1.72 0.014
 Leptin 0.64 0.041 0.62 0.027 0.79 NS
  N-terminal propeptide of type 1 collagen 5.94 0.004 4.20 0.011 2.47 0.049
 Osteocalcin 10.88 0.001 10.14 0.002 3.13 0.033
Change from baseline to week 4
  α-1 Antitrypsin 0.04 0.018 0.09 0.039 0.09 0.032
 C-reactive  protein 0.72 0.025 0.69 0.010 0.74 0.025
 Complement  3 0.02 0.004 0.02 0.003 0.01 0.001
 Haptoglobin 0.20 0.007 0.23 0.006 0.17 0.002
 Interleukin  6 0.36 0.003 0.52 0.013 0.43 0.002
  Serum amyloid P 0.30 NS 0.13 0.013 0.21 0.036
  Thyroxine binding globulin 0.33 NS 0.07 0.027 0.09 0.032
      Only biomarkers with signiﬁ  cant associations across multiple endpoints are shown.   
    OR represents the increased odds of clinical response for a 1 unit change on the log  2   scale or a doubling on the linear scale.   
    ASAS 20, at least 20% improvement in Assessment in SpondyloArthritis international Society response criteria; Bath ankylosing 
spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; NS, not signiﬁ  cant (p>0.05).     
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The NPV and PPV of this model were 90% and 65%, respec-
tively, compared with 45% and 66%, respectively, for the model 
utilising CRP alone (OR 1.08, p=0.609). 
  Baseline levels of TIMP-1 (OR 28.50, p=0.002) and P1NP (OR 
4.10, p=0.007) were the strongest predictors of an improvement 
in the BASFI score of 2 or greater from baseline to week 14. 
The NPV and PPV of this model were 85% and 61%, respec-
tively, compared with 54% and 73%, respectively, for the CRP-
only model. Of the three efﬁ  cacy comparisons, BASFI was the 
only endpoint that had a signiﬁ  cant predictive relationship with 
CRP at baseline (OR 1.47, p=0.017), although this result was less 
signiﬁ  cant than either TIMP-1 or P1NP at baseline. 
  These analyses indicated that panels of two or three bio-
markers were more strongly predictive of the various clinical 
endpoints in AS than CRP alone. In addition, CRP was not 
identiﬁ  ed as a contributor in the panel of biomarkers identi-
ﬁ  ed as predictive of clinical response for any of the endpoints 
evaluated. The only marker included in the predictive models 
that was associated with multiple clinical response measures 
was P1NP.     
  DISCUSSION 
  In this biomarker substudy of the GO–RAISE trial, we evaluated 
92 serum proteins and have shown that golimumab treatment was 
effective in modulating certain acute phase reactants (CRP, α-1 
antitrypsin, haptoglobin and von Willebrand factor), inﬂ  amma-
tory markers (IL-6, CCL5, MMP-3, TNF receptor II, macrophage 
inﬂ  ammatory protein 1β, TIMP-1, ICAM-1 and VEGF), and other 
selected proteins in patients with active AS. In addition, patients 
who achieved clinical response displayed a distinct serum protein 
signature compared with non-responders, thus implicating these 
inﬂ  ammatory markers in AS pathology. Strong associations were 
shown between the levels of speciﬁ  c markers (at baseline and also 
changes from baseline to week 4) and several measures of clini-
cal improvement (ASAS 20, BASDAI and BASFI) at week 14 of 
golimumab treatment. 
  Signiﬁ  cant OR associations were observed between baseline 
biomarker levels and the achievement of clinical improvement 
in several clinical measures at week 14. Strong associations 
between apolipoprotein C3, deoxypyridinoline, ENA-78, hap-
toglobin, insulin, IL-6, leptin, P1NP and osteocalcin at baseline 
and the achievement of at least two of the three clinical param-
eters (ASAS 20 response, change in BASFI or change in BASDAI) 
were observed at week 14. Associations between haptoglobin 
and clinical parameters were observed for both baseline levels 
(for ASAS 20 and change in BASFI at week 14) and the change in 
levels from baseline to week 4 (ASAS 20 and changes in BASFI 
and BASDAI at week 14). While the role of haptoglobin in AS 
and other inﬂ  ammatory disorders is not well characterised, hap-
toglobin was determined in a preliminary study to be overex-
pressed by more than threefold in patients with AS (n=32) when 
compared with 32 healthy control subjects.  17   Of note, lower 
baseline levels of leptin, apolipoprotein C3 and insulin were 
associated with the ASAS 20 response and improvement in 
BASFI at week 14 in golimumab-treated patients. Other studies 
have shown inconsistent results regarding associations between 
serum leptin levels and disease activity in patients with AS.  18     19   
Although the role of this protein is commonly associated with 
appetite regulation, serum leptin levels have been shown to cor-
relate with serum IL-6 and CRP levels, suggesting a possible role 
for leptin in the inﬂ  ammatory pathogenesis of AS.  19     20   In con-
trast, a recent publication  21   reported comparable leptin levels 
across patients with AS and age- and weight-matched control 
subjects, with no signiﬁ  cant changes in leptin concentrations fol-
lowing anti-TNF treatment. 
  We observed that higher osteocalcin and P1NP levels at base-
line were associated with ASAS 20 response and improvements 
in BASFI and BASDAI among golimumab-treated patients. 
Similarly, increased osteocalcin levels and a reduction in the bone 
resorptive potential of osteoclast precursors has been shown in 
a small cohort of AS patients (n=10) treated with another TNFα 
inhibitor.  22   Furthermore, it has also been shown that AS patients 
receiving anti-TNF treatment have increased osteocalcin levels 
associated with increases in the bone mineral density of the 
spine and hip.  11   P1NP is a more sensitive marker of bone for-
mation and is the propeptide of type 1 collagen. While levels 
of this marker have not previously been shown in association 
with clinical improvements in AS, P1NP has been observed to be 
independently related to osteocalcin levels, which in turn was 
 Table  3      Logistic regression model comparing the ability of baseline CRP and baseline biomarker levels for the prediction of clinical improvement at 
week 14   
Model (true/predicted)  *  ASAS 20 response BASDAI 50 response ≥2 Unit improvement in BASFI score
Baseline CRP only  *  NR R Accuracy  † NR R Accuracy  † NR R Accuracy  † 
  Non-responder 14 11 Speciﬁ  city: 56% 20 11 Speciﬁ  city: 65% 21 10 Speciﬁ  city: 68%
  Responder 11 39 Sensitivity: 78% 24 21 Sensitivity: 47% 18 27 Sensitivity: 60%
  Predictive value NPV 56% PPV 78%   NPV 45% PPV 66%   NPV 54% PPV 73%  
Baseline  biomarker *  NR R Accuracy *  NR R Accuracy *  N R Accuracy * 
  Non-responder 17 8 Speciﬁ  city: 65% 26 18 Speciﬁ  city: 59% 17 22 Speciﬁ  city: 61%
  Responder 5 45 Sensitivity: 90% 3 29 Sensitivity: 91% 3 34 Sensitivity: 85%
  Predictive value NPV 77% PPV 85%   NPV 90% PPV 65%   NPV 85% PPV 61%  
Predictors  ‡  Weight OR p value Weight OR p value Weight OR p value
 Immunoglobulin  M – – – 1.24 3.46 0.006 – – –
 Insulin -0.50 0.61 0.007 – – – – – –
 Leptin – – – -0.69 0.50 0.0004 – – –
  N-terminal propeptide of type I collagen 1.98 7.24 0.001 – – – 1.41 4.10 0.007
  Tissue inhibitor of metalloproteinases 1 – – – – – – 3.35 28.50 0.002
  Vascular endothelial growth factor – – – 0.79 2.20 0.026 – – –
   *  All  biomarker  values  were  log 2  -transformed before inclusion in the models. Both models are based on 76 patients.   
  †    Model accuracy (sensitivity, speciﬁ  city, NPV, PPV) was estimated using cross-validation.   
  ‡    Weights are the coefﬁ  cients in the logistic regression model. OR are the exponential of the weights. Multivariate p values are based on the inclusion of all terms in the model.   
    ASAS 20, at least 20% improvement in Assessment in SpondyloArthritis international Society response criteria; BASDAI 50, ≥50% improvement in the Bath ankylosing spondylitis 
disease activity index; BASFI, Bath ankylosing spondylitis functional index; CRP, C-reactive protein; NPV, negative predictive value; NR, non-responders; PPV, positive predictive value; 
R,  responders.   
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independently related to the bone mineral density of the lumbar 
spine and hip in 128 patients with AS.  23   
  We also explored whether individual markers or a combina-
tion of markers would signiﬁ  cantly predict clinical response to 
golimumab treatment in these patients with AS. The combina-
tion of baseline levels of P1NP and insulin in our model was 
superior to CRP alone in predicting the ASAS 20 response at 
week 14 of golimumab treatment. Similarly, the combination 
of baseline levels of leptin, immunoglobulin M and VEGF was 
more predictive of BASDAI 50 response at week 14 than CRP, 
and the combination of TIMP-1 and P1NP was more predic-
tive of a 2 unit or greater change in the BASFI score at week 
14. Across these three clinical measures, P1NP and insulin pro-
vided the strongest predictive power, with 77% NPV and 85% 
PPV for ASAS 20 response at week 14. This predictive power is 
substantially stronger than the results observed for CRP alone 
(NPV of 56% and PPV of 78%). Although numerous markers 
were consistently associated with multiple clinical measures, 
P1NP was the only marker to be identiﬁ  ed in predictive models 
for multiple clinical endpoints (ASAS 20 response and change 
in BASFI at week 14); however, insulin and leptin were also 
identiﬁ  ed in the logistic regression analysis as signiﬁ  cantly asso-
ciated with ASAS 20 response and change in the BASFI score 
at week 14. It is not surprising that there is limited overlap in 
the markers identiﬁ  ed in the predictive models due to the dif-
ferences inherent in the clinical efﬁ  cacy endpoints assessed in 
the study. For example, the BASDAI assesses patient-reported 
outcome and BASFI assesses physical function on a continuous 
scale, whereas the ASAS 20 response is a measure of AS includ-
ing patient-reported outcome measures and physical function 
in a responder index. 
  Although several of the markers identiﬁ  ed in this biomarker 
substudy are well known in inﬂ  ammatory diseases and bone 
remodelling (IL-6, osteocalcin and P1NP), less is known about 
the pathophysiological role of markers such as leptin and insu-
lin in AS. A number of small studies have indicated compa-
rable insulin levels and insulin sensitivity or resistance indices 
between patients with AS and matched healthy controls.  24    –    27   
However, results from another study have indicated beneﬁ  cial 
effects of anti-TNF therapy on insulin resistance and insulin 
sensitivity measures among patients with rheumatoid arthritis 
or AS and in those patients with the highest tertile of insu-
lin resistance scores.  28   The role of insulin in AS and the asso-
ciation with these clinical measures will require additional 
investigation. 
  This substudy had several limitations. First, the overall 
GO–RAISE study was primarily designed to evaluate the effect 
of golimumab on the signs and symptoms of AS, and the sub-
study was not powered for a deﬁ  nitive assessment of the asso-
ciations between biomarker levels and clinical improvement. 
The reported efﬁ  cacy measures were chosen to reﬂ  ect primary 
or major secondary endpoints in this study, thus comparisons of 
ASAS 20 with ASAS 40 or other variations of BASDAI or BASFI 
endpoints were not conducted. In addition, the earliest data col-
lection time point in the study was at week 4, and this time 
point was evaluated to ascertain if there were early biomarker 
changes that could reﬂ  ect later clinical results. Therefore, the 
effect of biomarker modulation earlier than 4 weeks is unknown, 
and early changes in biomarkers may reﬂ  ect their responses to 
or role as an acute phase reactant. Finally, if it had been col-
lected, RNA proﬁ  ling from peripheral blood mononuclear cells 
would have enabled the evaluation of a large number of genes 
and the inclusion of other key molecules involved in the TNFα 
inﬂ  ammatory pathway.  29     30   
  Clinical response to golimumab in patients with AS involves 
the modulation of several biomarkers, including those involved 
in the acute and inﬂ  ammatory phase of disease as well as in the 
downstream aspects relating to bone and cartilage metabolism 
and destruction. The results of this substudy showed strong asso-
ciations between serum biomarkers at baseline and an improve-
ment in several clinical response measures following golimumab 
treatment. The combination of baseline P1NP and insulin levels 
was the strongest predictor of an ASAS 20 response at week 
14 (77% NPV and 85% PPV); however, with 65% speciﬁ  city 
and 90% sensitivity, further studies will be needed to address 
their potential predictive utility in this clinical setting. While the 
authors agree that there is merit to an independent conﬁ  rmation 
of study ﬁ  ndings, the data collected from this study provide a 
valuable foundation for subsequent biomarker comparisons in 
this patient population. Insights from this study have suggested 
new combinations of soluble biomarkers that may play a role in 
the chronic inﬂ  ammation of AS. 
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